These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25267204)

  • 1. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I; Ladaique P
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Refractoriness to platelet transfusion].
    Tsurumi H; Hara T; Moriwaki H
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):332-4. PubMed ID: 9833505
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe neonatal alloimmune thrombocytopenia due to anti-HPA-3a.
    Boehlen F; Kaplan C; de Moerloose P
    Vox Sang; 1998; 74(3):201-4. PubMed ID: 9595650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet component transfusion and alloimmunization: Where do we stand?
    Moncharmont P
    Transfus Clin Biol; 2018 Sep; 25(3):172-178. PubMed ID: 29478960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP; Nambiar A
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA; Zulli R; Soares S; Castro Vd; Moraes-Souza H
    Clinics (Sao Paulo); 2011; 66(1):35-40. PubMed ID: 21437433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and identification of platelet-associated alloantibodies by a solid-phase modified antigen capture enzyme-linked immunosorbent assay method and its correlation to platelet refractoriness in multiplatelet concentrate-transfused patients.
    Jain N; Sarkar S; Philip J
    Immunohematology; 2014; 30(3):123-5. PubMed ID: 25695438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelets as immunogens.
    Waters AH
    Vox Sang; 1994; 67 Suppl 3():125-7. PubMed ID: 7975474
    [No Abstract]   [Full Text] [Related]  

  • 13. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation.
    Lucas G; Culliford S; Green F; Sidra G; Calvert A; Green A; Harrison P; Harvey J; Allen D; Smillie D; Masurekar A; Marks D; Russell N; Massey E
    Transfusion; 2010 Feb; 50(2):334-9. PubMed ID: 19874563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fetal/neonatal allo-immune thrombocytopenias: the unsolved questions].
    Kaplan C
    Transfus Clin Biol; 2005 Jun; 12(2):131-4. PubMed ID: 15950890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Occurrence of severe, persistent thrombocytopenia following allogeneic bone marrow transplantation, attributable to anti-HPA-1 allo-immunisation of the host].
    Parissiadis A; Bilger K; Laplace A; Berceanu A; Schwebel M; Froelich N; Cazenave JP; Hanau D; Tourne S; Lioure B
    Transfus Clin Biol; 2010 Oct; 17(4):265-8. PubMed ID: 20961787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of platelet transfusion refractoriness.
    Novotny VM
    Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.